Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

EMBO Molecular Medicine

Volumn 5, Issue 9, 2013, Pages 1383-1401

  Izumi, Kouji ^a,b   Fang, Lei Ya ^a   Mizokami, Atsushi ^b   Namiki, Mikio ^b   Li, Lei ^a   Lin, Wen Jye ^a,c   Chang, Chawnshang ^a,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Androgen receptor; CCL2; Epithelial mesenchymal transition; Prostate cancer; STAT3

Indexed keywords

ANDROGEN RECEPTOR; CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MACROPHAGE FUNCTION; MACROPHAGE RECRUITMENT; MALE; METASTASIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE METASTASIS; REGULATORY MECHANISM; TISSUE MICROARRAY; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN RECEPTOR; CCL2; EPITHELIAL-MESENCHYMAL TRANSITION; PROSTATE CANCER; STAT3;

ANIMALS; CHEMOKINE CCL2; HETEROGRAFTS; HUMANS; MACROPHAGES; MALE; MICE; MICROARRAY ANALYSIS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CCR2; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 84883366629     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201202367     Document Type: Article

References (50)

1. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, et al (2008) Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728
2. Alleva DG, Burger CJ, Elgert KD (1994) Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 153: 1674-1686
3. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305
4. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J (2007) Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 27: 4444-4453
5. Brabletz T (2012) To differentiate or not - routes towards metastasis. Nat Rev Cancer 12: 425-436
6. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Nelson PS, Liu XS, Brown M, Balk SP (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20: 457-471
7. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586
8. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743
9. Cherney RJ, Nelson DJ, Lo YC, Yang G, Scherle PA, Jezak H, Solomon KA, Carter PH, Decicco CP (2008) Synthesis and evaluation of cis-3, 4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett 18: 5063-5065
10. Cherney RJ, Brogan JB, Mo R, Lo YC, Yang G, Miller PB, Scherle PA, Molino BF, Carter PH, Decicco CP (2009) Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett 19: 597-601
11. Deatrick KB, Luke CE, Elfline MA, Sood V, Baldwin J, Upchurch GR, Jr, Jaffer FA, Wakefield TW, Henke PK (2013) The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling. J Vasc Surg DOI: 10.1016/j.jvs.2012.11.088
12. Denis L (1993) Prostate cancer. Primary hormonal treatment. Cancer 71: 1050-1058
13. Friedl P, Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147: 992-1009
14. Garcia JA, Rini BI (2012) Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 118: 2583-2593
15. Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS (1993) Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia. J Urol 149: 1586-1592
16. Gulley J, Figg WD, Dahut WL (2003) Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol: H&O 1: 49-57
17. Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012
18. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85
19. Henke PK, Pearce CG, Moaveni DM, Moore AJ, Lynch EM, Longo C, Varma M, Dewyer NA, Deatrick KB, Upchurch GR, Jr, et al (2006) Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol 177: 3388-3397
20. Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: Cancer J Clin 22: 232-240
21. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A (2000) Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 278: 9-13
22. Kaler P, Augenlicht L, Klampfer L (2009) Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 28: 3892-3902
23. Kasper S, Cookson MS (2006) Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin N Am 33: 201-210, vii
24. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, Lin WJ, Chang C (2009) Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 119: 3739-3751
25. Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, et al (2013) New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol 5: 14-26
26. Loberg RD, Day LL, Harwood J, Ying C, St. John LN, Giles R, Neeley CK, Pienta KJ (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8: 578-586
27. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9: 556-562
28. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H, Pienta KJ (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11: 1235-1242
29. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, et al (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804
30. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 105: 12182-12187
31. Potula HS, Wang D, Quyen DV, Singh NK, Kundumani-Sridharan V, Karpurapu M, Park EA, Glasgow WC, Rao GN (2009) Src-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. J Biol Chem 284: 31142-31155
32. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225
33. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ (2000) Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6: 1038-1045
34. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K (2007) Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5: 1015-1030
35. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727
36. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J Clin 61: 212-236
37. Sood V, Luke CE, Deatrick KB, Baldwin J, Miller EM, Elfline M, Upchurch GR, Jr, Wakefield TW, Henke PK (2010) Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. Thromb Haemost 104: 1174-1183
38. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al (2012) Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 72: 527-536
39. Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, et al (2012) CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 72: 2768-2779
40. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406
41. Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, Cunha GR, Gao WQ (2007) Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differ Res Biol Divers 75: 219-234
42. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY, Chang C (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 104: 12679-12684
43. Yamaoka M, Hara T, Kusaka M (2010) Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 16: 4319-4324
44. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, Huang KE, Lin H, Yeh SD, Altuwaijri S, Zhou X, et al (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 99: 13498-13503
45. Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, Wang RS, Chang YJ, Mendis-Handagama C, Hu L, et al (2006) Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci USA 103: 17718-17723
46. Zhang J, Lu Y, Pienta KJ (2010a) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 102: 522-528
47. Zhang J, Patel L, Pienta KJ (2010b) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21: 41-48
48. Zhang J, Patel L, Pienta KJ (2010c) Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Progress Mol Biol Transl Sci 95: 31-53
49. Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 24: 769-777
50. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, et al (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124: 615-629